INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member
August 08 2019 - 8:30AM
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, is pleased to announce that Edgardo (Ed)
Baracchini, Ph.D., has joined the company’s board of directors.
“Ed is a fantastic addition to our board of directors,” said RJ
Tesi, MD, INmune Bio’s Chief Executive Officer and Chief Medical
Officer. “He brings extensive business development and deal-making
experience to the company, which is a critical skill set, as we
continue to advance our three drug candidates through clinical
trials.”
Dr. Baracchini has an impressive biotech business development
background with over 25 years of experience in structuring and
negotiated research and development partnerships, mergers,
acquisitions and licensing agreements. He has negotiated over
80 business transactions with multinational pharmaceutical firms,
biotechnology companies and prominent universities which resulted
in transactions valued in excess of $5.3 billion. He
currently serves on the board of 4D Pharma PLC, as was previously
Chief Business Officer of Xencor, Inc. (Nasdaq: XNCR), a
biopharmaceutical company focused on autoimmune diseases. Prior to
this, Dr. Baracchini was associated with Metabasis Therapeutics,
where he quickly moved from the role of Vice President to Senior
Vice President of Business Development.
“INmune Bio has very exciting clinical trials in cancer and
Alzheimer’s disease,” said Baracchini. “I am looking forward to
working closely with its seasoned leadership team, each of whom
have demonstrated their own track record of success.”
About INmune Bio, Inc.INmune Bio, Inc. is a
publicly traded (NASDAQ: INMB) clinical-stage biotechnology company
developing therapies targeting the innate immune system to fight
disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that
is currently focused on Alzheimer’s disease. INKmune is a natural
killer (NK) cell therapeutic that primes the patient’s NK cells to
attack minimal residual disease, the remaining cancer cells that
are difficult to detect, which often cause relapse. INB03 inhibits
myeloid derived suppressor cells (MDSC), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint
inhibitors. XPro1595 targets neuroinflammation, which causes
microglial activation and neuronal cell death. INmune Bio’s product
platforms utilize a precision medicine approach for the treatment
of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. To learn more, please visit
www.inmunebio.com.
INmune Bio Contact: David Moss, CFO(858)
964-3720DMoss@INmuneBio.com
Media Contact: Antenna GroupHolly Dugan(201)
465-8019INmuneBio@AntennaGroup.com
Investor Contact: KCSA Strategic
Communications Valter Pinto / Daniela Guerrero PH: (212)
896-1254 / (347) 487-6187INmune@KCSA.com
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2023 to Aug 2024